Programme: **Wednesday 20 May**

4-5.30pm PARALLEL SESSION

Myopia: Evidence based assessment and management of myopic children in 2026

Myopia is estimated to impact almost half of the worlds' children in the next 20 years. High myopia is projected to increase sight-threatening myopia related complications. Consequently, measures to reduce myopia progression are increasingly being used to address this concern.
Globally, we have seen evolution of public health initiatives to delay myopia onset and progression. In addition, there is a growing presence of licensed and evidence-based interventions for slowing myopia progression in children. This has led to a need to review how we approach myopic children and a move away from simply considering their refraction in isolation. However, challenges remain when implementing this as standard of care.

In this session, we'll explore the latest research, clinical approaches, and innovations that are shaping myopia management—from optical and pharmaceutical interventions to patient education and public health strategies. Finally, we will put this together to explore a real-world myopia pathway. We aim to ensure delegates leave with actionable insights and a deeper understanding of approaches for the assessment and management of myopic children.

4.05-4.20pm Pre-Myopia and Public Health strategies: Evidence based approaches and impact, Dr Jane Fulton, Ulster University, UK

4.25-4.40pm Optical interventions for myopia control – What the evidence tells us and when we would use them, Professor Nicola Logan, Aston University, UK

4.45-5pm How to assess progression: Emmetropia vs Mean myopic growth - Dr Mark Bullimore, University of Houston, USA

5.05-5.20pm A real-world myopia management pathway: Moorfields UAE experience - Dr Imran Jawaid, Moorfields Eye Hospital Dubai, UAE